Valsartan monotherapy with 80 mg as the initial dose has shown considerable effectiveness in hypertensive patients, particularly those with congestive heart failure (CHF) and renal impairment, and as an alternative and/or add-on therapy in hypertensive patients not responding to or tolerating ACE inhibitors and β-blockers or diuretics, respectively10. Here, ACE is linked to congestive heart failure.